TheraRadar
← Back
Data updated: Jun 17, 2026

EUROFARMA

Big Pharma
RespiratoryDermatologyOncology Execution: Fair

EUROFARMA is a major pharmaceutical company focused on Respiratory, Dermatology, Oncology.

1963
Since
7
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

EUROFARMA at a Glance

  • Growing R&D activity with 16 trials in last 2 years
  • Fast trial execution (12 months median completion)

EUROFARMA's Key Drugs

EUROFARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

EUROFARMA's Recent FDA Approvals

New NDA/BLA approvals for EUROFARMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

EUROFARMA's Therapeutic Areas

EUROFARMA's approved drugs and pipeline span 5 therapeutic areas, led by Respiratory and Dermatology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Respiratory 26%
0 drugs Phase 3: 8
Dermatology 23%
2 drugs Phase 3: 4
Oncology 20%
0 drugs Phase 3: 5 Phase 2: 2
Infectious Disease 18%
3 drugs Phase 3: 1
Cardiovascular 13%
0 drugs Phase 3: 4

EUROFARMA Pipeline Snapshot

EUROFARMA has 24 active clinical programs from ClinicalTrials.gov — 22 Phase 3, 2 Phase 2 and 0 Phase 1.

22
Phase 3
2
Phase 2
0
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Respiratory pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 22/50 completed
  • • Speed: 12 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges